Two Sigma Securities’s Liminatus Pharma LIMN Stock Holding History

Two Sigma Securities’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-441	Closed	-$3.79K	–	2545
2026 Q1	$3.79K	Buy	441 +203	+85%	+$5.41K	﹤0.01%	1532
2025 Q4	$7.24K	Buy	+238	New	+$13.2K	﹤0.01%	1320

Other funds holding LIMN

CCA

Cygnus Capital Advisors Atlanta, Georgia $147M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Securities's LIMN Position: Q2 2026 in Review

Two Sigma Securities sold out of Liminatus Pharma (LIMN) in Q2 2026, closing a stake of 441 shares — an estimated $3.79K sold.

Two Sigma Securities first reported a position in LIMN in Q4 2025 and held it in 2 quarters. The position peaked at $7.24K in Q4 2025. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

Two Sigma Securities reported no remaining Liminatus Pharma position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 441 Liminatus Pharma shares in Q2 2026, an estimated $3.79K.
Two Sigma Securities first reported a position in Liminatus Pharma in Q4 2025 and held it in 2 quarters.
Two Sigma Securities's Liminatus Pharma position peaked at $7.24K in Q4 2025.
14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.